Ancient Flu Infection Mechanism Found
Each year the flu virus sends 13,500 Australians to the hospital and causes more than 3000 deaths among those aged over 50.
The global burden is also staggering, with more than 5 million cases of infection annually with up to 10 per cent resulting in death.
The RMIT senior authors, Dr Stavros Selemidis (ARC Future Fellow) and Dr Eunice To (first author), collaborated with Professor Doug Brooks from University South Australia, Professor John O’Leary from Trinity College Dublin, Monash University’s Professor Christopher Porter, and other scientists and clinicians to investigate how viruses cause disease in humans.
The researchers discovered that a 1.5 billion-year-old cell biological process found in plants, fungi and mammals enhances viral disease in mice and highly likely also in humans.
They identified a protein, NOX2 oxidase, that is activated by viruses, including influenza, rhinovirus (the common cold), dengue and HIV.
Once activated, NOX2 oxidase suppresses the body’s key antiviral reaction and its ability to fight and clear the viral infection, which in turn results in a stronger or more virulent disease in mice.
The study also investigated a new prototype drug to treat these debilitating viral diseases.
The researchers found that the NOX2 oxidase protein activated by the viruses is located in a cell compartment called endosomes. They carefully modified a chemical that inhibits or restrains the activity of NOX2 oxidase.
Their customized drug was found to be very effective at suppressing disease caused by influenza infection.
Selemidis, head of the Oxidant and Inflammation Biology Group within the Chronic Infectious and Inflammatory Diseases program at RMIT, said: “Current treatment strategies are limited as they specifically target circulating viruses and have either unknown or very little effect against new viruses that enter the human population.
“We have identified a protein of the immune system that contributes to the disease caused by flu viruses irrespective of their strain.
“We also developed a novel drug delivery system to target this protein, which drastically alleviated the burden of viral disease.
“The strength of this work is the multidisciplinary approach taken and the degree of collaboration. It includes researchers and clinicians from eight universities across Australia, the United States and Ireland.
“This work attracted considerable interest at the NADPH Oxidase GORDON conference in the USA last year.”
To said: “This work identifies a treatment strategy that has the potential to alleviate the symptoms caused by some of the most devastating viruses worldwide, including the flu.”
Professor Calum Drummond, Deputy Vice-Chancellor Research and Innovation and Vice-President at RMIT, said the project held immense promise.
“The unique partnership between Dr Selemidis’ laboratory at the School of Health and Biomedical Sciences at RMIT and his collaborators continues.
“Dr Selemidis’ laboratory and his collaborators are pursuing further research to aid development of novel drugs for further trials and this is showing great potential,” Drummond said.
To, E., Vlahos, R., Luong, R., Halls, M., Reading, P., King, P., Chan, C., Drummond, G., Sobey, C., Broughton, B., Starkey, M., van der Sluis, R., Lewin, S., Bozinovski, S., O’Neill, L., Quach, T., Porter, C., Brooks, D., O’Leary, J. and Selemidis, S. (2017). Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. Nature Communications, 8(1).
This article has been republished from materials provided by RMIT. Note: material may have been edited for length and content. For further information, please contact the cited source.
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by NovartisNews
The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity.READ MORE
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
Comments | 0 ADD COMMENT
Microbiome Futures: A Global Translational Roadmap
May 23 - May 23, 2018
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018